Insider Selling: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director Sells 25,000 Shares of Stock

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director N Anthony Coles sold 25,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $41.18, for a total transaction of $1,029,500.00. Following the sale, the director now owns 25,928 shares in the company, valued at approximately $1,067,715.04. The sale was disclosed in a legal filing with the SEC, which is available at this link.

N Anthony Coles also recently made the following trade(s):

• On Friday, May 10th, N Anthony Coles sold 50,000 shares of Cerevel Therapeutics stock. The stock was sold at an average price of $42.10, for a total transaction of $2,105,000.00.

Cerevel Therapeutics Stock Down 2.3 %

Cerevel Therapeutics stock traded down $0.93 during mid-day trading on Wednesday, reaching $40.30. The stock had a trading volume of 4,680,757 shares, compared to its average volume of 1,555,320. The company has a market capitalization of $7.34 billion, a price-to-earnings ratio of -14.76 and a beta of 1.40. The company has a 50-day moving average price of $41.49 and a two-hundred day moving average price of $41.83. Cerevel Therapeutics Holdings, Inc. has a one year low of $19.59 and a one year high of $43.59. The company has a debt-to-equity ratio of 0.60, a current ratio of 10.22 and a quick ratio of 10.22.

Cerevel Therapeutics (NASDAQ:CERE) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). On average, analysts expect that Cerevel Therapeutics Holdings, Inc. will post -2.59 EPS for the current fiscal year.

Hedge Funds Weigh In On Cerevel Therapeutics

A number of hedge funds have recently bought and sold shares of CERE. Headlands Technologies LLC purchased a new position in Cerevel Therapeutics in the 1st quarter worth about $26,000. Pacific Capital Wealth Advisors Inc. purchased a new position in Cerevel Therapeutics in the 4th quarter worth about $71,000. Centaurus Financial Inc. purchased a new position in Cerevel Therapeutics in the 4th quarter worth about $119,000. GAM Holding AG purchased a new position in Cerevel Therapeutics in the 4th quarter worth about $212,000. Finally, Virtu Financial LLC purchased a new position in Cerevel Therapeutics in the 4th quarter worth about $246,000. Institutional investors own 87.73% of the company’s stock.

Cerevel Therapeutics Company Profile

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.